more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

by Debanjana Dey Published on February 25,2022

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research Published on February 25,2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on February 25,2022

Here is how Henry Schein (HSIC) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research Published on February 25,2022

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research Published on February 25,2022

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research Published on February 25,2022

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.